PBRM1 and nonpapillary renal cell carcinoma: In this context, a comprehensive understanding of the molecular mechanisms of PBRM1 mutation in patients with ccRCC treated with ICIs could be critical for the development of a novel biomarker and to help predict which patients are most likely to benefit from ICIs treatment.